Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA1A | P35348 | 2/20 | 0.47 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.47 |
| ▸ | SIRT1 | Q96EB6 | 2/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CNR1 | P21554 | 2/20 | 0.34 |
| ▸ | CNR2 | P34972 | 2/20 | 0.34 |
| ▸ | FABP4 | P15090 | 1/20 | 0.33 |
| ▸ | PARP1 | P09874 | 1/20 | 0.33 |
| ▸ | GRM7 | Q14831 | 1/20 | 0.33 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10165961 | 0.87 | ADRA1A (0.46) | ADRA1AADRA2ASIRT1CYP1A2PARP1 | |
| SCHEMBL559163 | 0.85 | PARP1 (0.47) | CYP1A2PARP1PIN1 | |
| SCHEMBL1847083 | 0.77 | PIN1 (0.52) | ADRA1AADRA2ACYP1A2PIN1 | |
| SCHEMBL20478665 | 0.77 | PIN1 (0.52) | ADRA1AADRA2ACYP1A2PIN1 | |
| SCHEMBL835462 | 0.76 | ADRA1A (0.52) | ADRA1AADRA2ACYP1A2PARP1GRM7 | |
| SCHEMBL10205808 | 0.73 | PARP1 (0.47) | CYP1A2PARP1PIN1 | |
| SCHEMBL9325738 | 0.72 | CA1 (0.53) | — | |
| SCHEMBL1844443 | 0.72 | CA1 (0.53) | — | |
| SCHEMBL559102 | 0.72 | PARP1 (0.46) | ADRA1ASIRT1CYP1A2PARP1PIN1 | |
| SCHEMBL11957278 | 0.72 | ADRA2A (0.43) | ADRA1AADRA2APARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120035194-A1 | SUBSTITUTED 2-AMINO-FUSED HETEROCYCLIC COMPOUNDS | PFIZER INC. (US) | 2012-02-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120035194-A1 | SUBSTITUTED 2-AMINO-FUSED HETEROCYCLIC COMPOUNDS | MAPK1, SLC5A1, ATF1 | ADRA1A 161/4885ADRA2A 273/4885SIRT1 539/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.